WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), trading as WuXi Bio (2269.HK), proudly announces its sweeping victory at the 2024 CDMO Leadership Awards. The company secured top honors across all six categories – Capabilities, Compatibility, Expertise, Quality, Reliability, and Service – within each of the three distinct groups: Big Pharma, Small Pharma, and Overall. Notably, WuXi Biologics attained the esteemed title of “Champion” for its exceptional ratings in Compatibility and Service within the Small Pharma segment.
This remarkable achievement marks the seventh consecutive year that WuXi Biologics has been recognized by the CDMO Leadership Awards. The company’s unwavering commitment to excellence has solidified collaborations with global clients, offering unparalleled expertise, cutting-edge technologies, and comprehensive biologics research, development, and manufacturing services. These efforts enable the swift and cost-effective progression of biologics and vaccines from conception to commercial production.
Over the past year alone, WuXi Biologics has facilitated an impressive 110 IND filings and has surpassed 1,000 client quality audits. Additionally, the company has successfully completed 33 regulatory inspections conducted by esteemed bodies such as the U.S. FDA, EU EMA, China NMPA, and other global regulatory agencies. With a remarkable PPQ success rate exceeding 97% for both drug substance and drug product manufacturing, WuXi Biologics boasts an unparalleled track record of premier quality.
Dr. Chris Chen, CEO of WuXi Biologics, expressed his gratitude, stating, “We are honored to receive recognition from pharmaceutical companies across all categories of the CDMO Leadership Awards. This acknowledgment underscores the exceptional dedication of our global workforce and the trust we have earned in facilitating our clients’ efficient progression of breakthrough treatments to market, ultimately benefiting patients.”
The CDMO Leadership Awards, presented by Outsourced Pharma and Life Science Leader, recognize excellence in contract manufacturing organizations. For the 2024 awards, 72 such organizations, identified through authoritative third-party research, were evaluated on more than 23 distinct performance metrics by pharmaceutical and biopharmaceutical companies that have utilized outsourcing services within the past 18 months.\
